Physician profile
Vijay M Patel
NPI 1326260837
$72,105.26
in general payments reported to CMS, 2019-2025
72 companies · $233 in 2025
The $233 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $11K · 2021: $21K · 2022: $10K · 2023: $1,103 · 2024: $1,256 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,586 · Education: $6.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,585.66 |
| Education | $6.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $20,176.87 | 2019-2024 | Alunbrig, Vpriv, Iclusig |
| Bayer Healthcare Pharmaceuticals INC. | $19,011.61 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $17,133.06 | 2019-2024 | Libtayo |
| Heron Therapeutics, INC. | $3,488.18 | 2019-2020 | |
| Genzyme Corporation | $2,277.07 | 2019-2024 | |
| Pfizer INC. | $1,794.77 | 2019-2024 | |
| Celgene Corporation | $1,532.21 | 2021-2025 | Pomalyst, Reblozyl, Opdivo |
| Amgen INC. | $780.79 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $557.78 | 2019-2025 | Imfinzi, Enhertu |
| Daiichi Sankyo INC. | $461.66 | 2020-2024 | Enhertu |
| Alexion Pharmaceuticals, INC. | $457.76 | 2019-2022 | |
| Seagen INC. | $404.83 | 2019-2023 | Tukysa, Adcetris |
| Novartis Pharmaceuticals Corporation | $362.49 | 2019-2025 | |
| Nutech Spine, INC. | $280.13 | 2021 | |
| Genentech USA, INC. | $222.08 | 2019-2024 | Venclexta, Polivy, Tecentriq |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $214.63 | 2021 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Janssen Biotech, INC. | $196.72 | 2019-2024 | Erleada, Darzalex, Talvey |
| Athenex Pharmaceutical Division, LLC | $175.00 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $169.54 | 2019-2024 | Somatuline Depot, Onivyde |
| Ethicon US, LLC | $148.68 | 2022 | |
| Tesaro, INC. | $136.94 | 2019 | |
| Myovant Sciences INC. | $122.44 | 2021 | |
| Edwards Lifesciences Corporation | $116.46 | 2019 | |
| Novo Nordisk INC | $107.39 | 2020 | |
| Gilead Sciences, INC. | $88.75 | 2021-2024 | Trodelvy |
| Galvanize Therapeutics, INC | $84.22 | 2023 | Aliya System |
| E.R. Squibb & Sons, L.L.C. | $77.81 | 2019-2024 | Eliquis, Opdivo |
| Astellas Pharma US INC | $67.89 | 2023-2025 | Xtandi, Padcev, Xospata |
| Taiho Oncology, INC. | $65.67 | 2024-2025 | |
| Genmab U.S., INC. | $58.01 | 2023-2024 | Epkinly |
| Abbvie INC. | $57.26 | 2019-2024 | |
| Incyte Corporation | $54.97 | 2022-2024 | Monjuvi |
| Glaxosmithkline, LLC. | $53.69 | 2022-2024 | Zejula, Jemperli |
| Merck Sharp & Dohme LLC | $51.16 | 2019-2024 | Keytruda |
| Karyopharm Therapeutics INC. | $50.83 | 2023-2024 | Xpovio |
| Servier Pharmaceuticals LLC | $49.67 | 2022-2024 | |
| Aveo Pharmaceuticals, INC. | $47.27 | 2023-2024 | Fotivda |
| Octapharma USA, INC. | $41.57 | 2024-2025 | Octagam Immune Globulin (Human) |
| G1 Therapeutics, INC. | $39.11 | 2022-2023 | Cosela |
| Eisai INC. | $38.35 | 2023-2024 | |
| Sobi, INC | $37.73 | 2024 | |
| Tersera Therapeutics LLC | $37.33 | 2023 | Zoladex |
| Beigene USA, INC. | $35.37 | 2022-2023 | Brukinsa |
| Emd Serono, INC. | $33.44 | 2024 | |
| Array Biopharma INC | $33.32 | 2022-2023 | Mektovi, Braftovi, Lorbrena |
| Jazz Pharmaceuticals INC. | $29.60 | 2024 | |
| Csl Behring | $29.46 | 2022-2025 | Idelvion, Afstyla |
| Cti Biopharma Corp. | $28.47 | 2022-2023 | Vonjo |
| Apellis Pharmaceuticals, INC. | $28.06 | 2023 | Empaveli |
| Pharmacyclics LLC, An Abbvie Company | $26.22 | 2019 | |
| Pharmaessentia USA Corporation | $25.03 | 2024 | Besremi |
| Johnson & Johnson Health Care Systems INC. | $25.00 | 2023 | Uptravi |
| Secura Bio, INC. | $23.97 | 2019 | |
| Stemline Therapeutics INC. | $21.60 | 2023 | Orserdu |
| Pharmacosmos Therapeutics INC. | $19.96 | 2024 | Cosela |
| Napo Pharmaceuticals INC | $19.28 | 2024 | Gelclair Concentrated Oral Gel |
| Rigel Pharmaceuticals, INC. | $18.87 | 2019-2024 | Rezlidhia, Tavalisse |
| Agios Pharmaceuticals, INC. | $18.76 | 2024 | |
| Myriad Genetic Laboratories, INC. | $18.43 | 2022 | |
| Kite Pharma, INC. | $17.42 | 2022 | |
| Morphosys, US INC. | $16.43 | 2021 | |
| Lilly USA, LLC | $16.41 | 2019 | |
| Global Blood Therapeutics, INC. | $13.84 | 2021 | |
| Mirati Therapeutics, INC. | $13.63 | 2024 | Krazati |
| Ge Healthcare | $13.61 | 2022 | |
| Aurobindo Pharma USA, INC. | $13.51 | 2019 | |
| Boston Scientific Corporation | $12.28 | 2019 | |
| Sirtex Medical INC | $11.33 | 2020 | |
| Biocartis US, INC | $11.00 | 2023 | Idylla |
| Veracyte, INC. | $0.58 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.